Quoin in line for second priority review voucher if rare paediatric drug approved

RegulatoryQRX003Positive

AI Analysis

Summary

Quoin has received a second rare paediatric disease designation for its lead asset QRX003, positioning the company to potentially earn a second priority review voucher upon approval.

Outcome Details

Received second rare paediatric disease designation

Importance:5/10

Sentiment:

0.60

rare_diseasepediatricpriority_review_voucherregulatory_designation

Read the original article

Published by Pharmaceutical Technology on September 8, 2026 4:28 PM

Read Original